PRINT THIS PAGE US Cerberus Capital bids for E500m blood products business13/08/2004. Source: AltAssets. 
 US turnaround specialist Cerberus Capital Management has entered into exclusive talks to buy Bayer's blood products unit for around E500m. The private equity firm is making its offer in conjunction with Precision Pharma, a services provider to the pharmaceutical and biotechnology industries.
A number of other private equity firms have also expressed an interest in the company, including Bain Capital and Carlyle. But Cerberus is now understood to be leading the field, according to a report by Reuters.
The blood products unit was put up for sale in October last year. The sale excludes the unit's haemophilia drug Kogenate.
Copyright © 2004 AltAssets
|
